Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma
Public ClinicalTrials.gov record NCT02723006. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label, Phase 1b, Multi-Arm Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Patients With Advanced Melanoma
Study identification
- NCT ID
- NCT02723006
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Enrollment
- 22 participants
Conditions and interventions
Conditions
Interventions
- TAK-202 Drug
- TAK-580 Drug
- ipilimumab Drug
- nivolumab Drug
- vedolizumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 21, 2016
- Primary completion
- May 10, 2018
- Completion
- May 10, 2018
- Last update posted
- Mar 4, 2024
2016 – 2018
United States locations
- U.S. sites
- 14
- U.S. states
- 11
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Arizona Cancer Center | Tucson | Arizona | — | — |
| University of California Los Angeles - Jonsson Comprehensive Cancer Center | Los Angeles | California | — | — |
| University of California San Francisco Medical Center | San Francisco | California | — | — |
| University of Colorado Cancer Center | Aurora | Colorado | — | — |
| Emory University Hospital | Atlanta | Georgia | — | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | — | — |
| Massachusetts General Hospital Cancer Center | Boston | Massachusetts | — | — |
| Virginia Piper Cancer Institute | Minneapolis | Minnesota | — | — |
| Washington University School of Medicine | St Louis | Missouri | — | — |
| New York University Langone Medical Center | New York | New York | — | — |
| Saint Luke's Cancer Center - Bethlehem | Easton | Pennsylvania | — | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | — | — |
| Texas Oncology-Baylor Charles A. Sammons Cancer Center | Dallas | Texas | — | — |
| Inova Fairfax Hospital | Fairfax | Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02723006, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 4, 2024 · Synced May 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02723006 live on ClinicalTrials.gov.